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Liver disease results from a dynamic pathological process associated with cellular and genetic alterations, which may progress
stepwise to liver dysfunction. Commonly, liver disease begins with hepatocyte injury, followed by persistent episodes of cellular
regeneration, inflammation, and hepatocyte death that may ultimately lead to nonreversible liver failure. For centuries, herbal
remedies have been used for a variety of liver diseases and recent studies have identified the active compounds that may interact
with liver disease-associated targets. Further study on the herbal remediesmay lead to the formulation of next generationmedicines
with hepatoprotective, antifibrotic, and anticancer properties. Still, the pharmacological actions of vast majority of herbal remedies
remain unknown; thus, extensive preclinical studies are important. In this review, we summarize progress made over the last five
years of the most commonly used preclinical models of liver diseases that are used to screen for curative herbal medicines for
nonalcoholic fatty liver disease, liver fibrosis/cirrhosis, and liver. We also summarize the proposed mechanisms associated with
the observed liver-protective, antifibrotic, and anticancer actions of several promising herbal medicines and discuss the challenges
faced in this research field.
1. Introduction
Hepatic disease refers to a constellation of disorders of the
liver that can lead to decompensated liver function. The
liver is a very important organ that is mainly responsible for
vital functions such as detoxification and glucose and lipid
metabolism as well as the synthesis of many key enzymes
that regulate these metabolic processes. Acute liver disease
is defined as a rapid hepatic dysfunction that occurs in the
absence of previous history of chronic liver disease; it is
caused, for example, by excessive consumption of antibiotics
or acetaminophen. By contrast, chronic liver disease is a long-
term dynamic process that involves persistent hepatocytic
destruction and regeneration. Major risk factors for chronic
liver disease are hepatitis B viral and hepatitis C viral (HBV
and HCV) infection and alcoholic liver-induced injury lead-
ing to alcoholic liver disease (ALD) as well as a constellation
of metabolic disorders that can lead to nonalcoholic fatty
liver disease (NAFLD). Liver exposure to these risk factors
gradually results in hepatocytic injury associated with tissue
infiltration of inflammatory cells and altered transcriptome
in the affected cell populations. As a result, both liver scarring
and regeneration are triggered which, if left unchecked, will
ultimately progress to profound changes in liver architecture
and liver cirrhosis. In addition, patients with cirrhosis have
a higher risk of developing hepatocellular carcinoma (HCC)
[1].
The incidence of NAFLD is highest among all chronic
liver diseases in the United States where it was responsible
for 75% of all cases in 2008 [2]. Globally, the prevalence
of NAFLD ranges from 10 to 35% depending on different
diagnostic tools and populations studied. For nonalcoholic
induced steatohepatitis (NASH), between 3 and 5% of the
global population is at risk [3]. In clinic, pioglitazone or
vitamin E is only given to patients with advanced stage of
NASH who failed lifestyle intervention due to the potential
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risk of the treatment in inducing stroke [4]. Global mor-
tality from liver cirrhosis rose to over 1 million in 2010,
accounting for 2% of all deaths worldwide. Approximately
16 out of every 100,000 people died due to liver cirrhosis
worldwide, and the incidence is greater in South and Cen-
tral Asia as well as Eastern European countries [5]. Liver
transplantation remains the only intervention for patients
with liver cirrhosis, as alternative drug therapies are not
available in the clinic. Antifibrotic therapy is emerging as a
possible option as several antifibrotic candidates have been
shortlisted preclinically and await further study [6]. Similar
to liver cirrhosis, surgical removal and liver transplantation
are the most effective treatment for HCC. However, not
all patients are suitable for liver surgery as the cancer may
have spread and the 5-year survival rate was reported to
be about 15% for patients diagnosed with HCC [7]. There
is currently an unfilled medical need to find alternatives
to liver transplantation by combating inflammation and the
production of reactive oxygen species that are key aspects
of chronic liver diseases. In many countries like China,
there is a rich history of using herbal medicine to treat
liver diseases. Due to the antioxidant and anti-inflammatory
nature of these botanicals, their active ingredients could lead
to the development of novel hepatoprotective, antifibrotic,
and antiliver cancer therapies. To date, plant-based products
such as Fuzheng Huayu formula and silymarin have been
well documented for use in liver diseases [8]. Fuzheng Huayu
formula, an FDA-approved Chinese medicinal formulation,
is now undergoing phase IV clinical trial for patients with
cirrhosis secondary to HBV infection in China and phase
II clinical trial had been completed for chronic hepatitis
C patient in US [9]. Although some herbal remedies hold
promise for attenuating or reversing the progression of liver
diseases, other compounds may be toxic and damage the
liver [10].Therefore, preclinical studies of dose escalation and
efficacy testing should be thoroughly conducted in animal
models in order to provide a better understanding of safety
and efficacy before advancing herbal remedies to clinical
studies.
Appropriate in vitromodels for NAFLD and liver fibrosis
remain to be developed. Furthermore, despite extensive use
of immortalized cell lines and primary cultures, effective
systems for high throughput drug screening are lacking. In
part, this is due to the multifactorial nature of liver disease
that is not amenable to investigation through simple in vitro
cell models.
In this review, we aim to systematically review the most
commonly used animal models that were employed to screen
and study the efficacy of herbal medicines for liver diseases.
This may serve as a guiding tool for selecting the appropriate
liver disease model for herbal medicine screening as well as
facilitating further exploration of studied herbal remedies for
clinical applications.
2. Animal Models for NAFLD and NASH
NAFLD is an idiopathic pathological condition where exces-
sive fat deposition in the liver is caused by factors other
than chronic alcohol consumption. If untreated, NAFLDmay
further progress to nonalcoholic steatohepatitis or NASH
and then liver fibrosis/cirrhosis and eventually liver cancer.
NAFLD is more prevalent in patients with obesity, diabetes,
insulin resistance, and hypertension, which suggests that it
is the manifestation of an untreated underlying metabolic
dysfunction.
Steatosis or the abnormal accumulation of fats in hep-
atocytes is thought to be the original disease-causing event
leading to further dysfunction through oxidative stress,
fatty acid and inflammatory cytokine-mediated liver injury,
and apoptosis as well as changed lipid partitioning [11].
Steatosis divides into two general types: macrovesicular and
microvesicular, which differ with respect to the number and
size of lipid vacuoles and to the position of the nucleus
in the cytoplasm. In macrovesicular steatosis, lipid vacuoles
are large and the nucleus tends to push aside, while in
microvesicular steatosis the nucleus is usually not affected.
NAFLD accounts for approximately 5% of all liver steatosis
[12]. However, in NASH, several other pathologies were
observed, such as hepatocellular ballooning and intralobular
and inflammatory infiltration with immune cells [13].
As mentioned earlier, liver pathology can progress from
obesity and insulin resistance to macrovesicular/micro-
vesicular steatosis, hepatocellular ballooning, and intralob-
ular inflammation. At the biochemical level, there is a
malfunction in lipid metabolism consisting of increased long
chain fatty acid influx and altered fatty acid synthesis as well
as decreased triglyceride production. Broadly, two types of
animal models for NAFLD/NASH have been described but
neither faithfully reflects the human conditions. In one type
of the model, the disease is induced by a genetic modification
that targets any one of the processes mentioned above while
in the other it is caused by altered dietary intake. The
ob/ob, db/db, adiponectin null, and KK-Aymodels have been
routinely employed to study the development of NAFLD.
However, these models do not directly progress to steatohep-
atitis but require additional insults, such as various dietary
treatments or the injection of hepatotoxins. On the other
hand, diet-based models such as the methionine and choline
deficiency (MCD)model or the high fat diet (HFD)model are
easier to develop and present some of the histological features
of human diseases. However, disease development in these
models can vary substantially based on the composition of
the diets and the duration of experiments.
The HFD model is most commonly used to explore the
effect of herbal medicines on NAFLD and NASH. After 4
months, total fat/body weight was found to be five times
higher in experimental HFD mice than in na¨ıve mice.
HFD mice had higher total serum cholesterol, triglyceride,
and insulin levels as well as impaired glucose tolerance
as compared to na¨ıve mice. All these suggest pathological
initiation of NAFLD. Administration of rhein, from Rheum
palmatum L. after 40 days of HFD, normalized liver fat
levels and improved insulin resistance [14]. In another study
by Xiao et al. [15], the histopathological modifications of
NASH such as hepatocytic necrosis and infiltration with
inflammatory cells were observed after 8 weeks of HFD.
Collagen formation detected by Sirius red staining also sug-
gested that the disease was progressing from steatohepatitis
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to hepatic fibrosis. Treatment with Lycium barbarum polysac-
charides for 4 weeks reduced insulin resistance and obesity
as well as improving the histopathological changes incurred
by HFD. Herbal medicines have also shown promising
results in the MCD mouse model, where as previously
mentioned, methionine and choline are absent from diet
[16]. These components are required for beta-oxidation and
VLDL synthesis and their dietary suppression leads to fatty
acid accumulation and oxidative stress in hepatocytes. A
recent study showed that, after eight weeks of MCD, there
was observable macrovesicular steatosis, inflammation, and
hepatocytic necrosis. Administration of Fuzheng Huayu for-
mula ameliorated these changes through downregulation of
CYP2E1 and HO-1, markers of oxidative stress. In addition,
TNF-𝛼 and IL-6 were similarly downregulated in this study
[17].
Animal models in which liver disease is induced by
a combination of selected genetic backgrounds, diets, and
the administration of hepatotoxins have also been pro-
posed [18, 19]. In the study by Ma et al., ApoE (−/−)
mice with HFD showing signs of NAFLD had ameliorated
pathological changes after being fed with Huanglian Jiedu
extract [20]. One possible explanation for this effect is
promotion of phagocytosis by the increased population of
M2 macrophages. Similarly, administration of the Japanese
herbal medicines Sho-saiko-to and Juzen-taiho-to in MCD-
fed db/db mice for 4 weeks reduced lobular inflammation
and liver ballooning [21]. In the above models, SREBP-
1c, adiponectin, PGC-1 alpha, and FABP were frequently
used as biochemical markers to monitor lipid and energy
metabolism functions. Overexpression of SREBP-1c induced
lipid synthesis and reduced VLDL efflux and lipid oxidation
while increasing triglyceride deposition in hepatocytes [22].
Adiponectin is another important cytokine that regulates
glucose metabolism and fatty acid breakdown. It is reported
that susceptibility for liver fibrosis in adiponectin knockout
mice is higher compared to na¨ıvemice [23]. A Japanese herbal
medicine, bofutsushosan, ameliorated hepatic steatosis and
inflammation through increased plasma adiponectin levels
and reduced SREBP-1c expression. Simultaneously, bofut-
sushosan also enhanced fatty acid oxidation and reduced
inflammation through upregulation of 𝛼/𝜆-PPAR [24]. Sim-
ilar findings were reported for ping-tang recipe that greatly
enhanced 𝛼/𝜆-PPAR expression while reducing that of the
lipogenic genes, SREBP-1c, FAS, and L-FABP [25]. Pro-
posed mechanisms for the observed effects of several herbal
medicines against NAFLD and NASH together with the
investigated animal models are summarized in Table 1.
3. Animal Models for Liver
Fibrosis and Cirrhosis
Liver fibrosis is a progressive disease that is caused by
viral induced hepatitis, alcoholic induced liver injury,
NAFLD/NASH, chronic biliary retention, or parasitic infec-
tion induced injury [26]. The underlying pathophysiological
process consists of overlapping cycles of wound healing
and cell necrosis that ultimately leads to accumulation of
extracellular matrix containing collagen and other matrix
components [27]. An important event in fibrogenesis is the
formation of hepatic myofibroblasts that secrete collagen. If
left unchecked, the process results in the complete destruc-
tion of liver architecture with hepatic insufficiency that is
the marker of a more severe process of cirrhosis. Ultimately,
portosystemic shunting leads to liver failure [28]. To date,
there is no effective treatment for liver fibrosis or cirrhosis.
Whether or not these processes are reversed or arrested in
their progression is a matter of current controversy. Yet,
animal studies have shown that in some cases experimentally
induced liver fibrosis can be reversed using botanical extracts.
Liver fibrogenesis can commonly be induced in animal
settings by cholestasis or administration of hepatotoxins. In
some studies, fibrosis was induced using longer-term models
of alcoholic or nonalcoholic liver injury or by a combination
of the two [29]. Recently, models of gene-modifiedmice were
established by knocking down the MDR2 gene or by overex-
pressing TGF-𝛽1 [30, 31].The administration of hepatotoxins
to induce liver injury in rodents is a model that is commonly
used in herbal medicine studies. Liver injury by carbon
tetrachloride (CCl
4
) administration is more frequently used
than thioacetamide (TAA) or dimethyl/diethyl nitrosamine
(DEN) due to short onset of disease development and the
direct cytotoxic effect of CCl
4
on hepatocytes. CCl
4
induced
early fibrosis can be detected within two weeks after the first
administration, and 5 to 7 weeks are sufficient to detect all the
physiological symptoms of liver fibrosis. Continuous admin-
istration of CCl
4
will eventually lead to liver cirrhosis. The
immediate cytotoxic effect of CCl
4
on hepatocytes recruits
inflammatory cells and induces secretion of proinflammatory
cytokines leading to necrosis. Scarring occurs as a result of
persistent cycles of cell death and is followed by hepatocytic
regeneration/proliferation processes [27]. A study by Zhou et
al. [32] showed that 6 weeks of intraperitoneal CCl
4
injection
3 times per week resulted in multiple scarring/fibrotic events
such as bridged vessels, fibrous septa, and even regenerative
nodules. Treatment with Xuefuzhuyu starting at week 4
ameliorated the hepatic stellate cells (HSC) activation and
ECM formation and reduced expression of 𝛼-SMA and
collagen I. Another study conducted by Shen et al. [33]
also showed that treatment with Diwu Yanggan in a 6-week
CCl
4
model attenuated epithelial-to-mesenchymal cellular
transition, a commonly observed condition in fibrogenesis,
through upregulation of E-cadherin and downregulation
of vimentin. Compared to CCl
4
, disease modelling using
TAA and DEN (a carcinogen) requires longer exposure time
to induce HCC. In all these cases and irrespective of the
causative agent, disease development is remarkably similar
across the models. For example, intraperitoneal injection of
TAA for 6 weeks increased fibrous septa, portal tract, and
liver sinusoids as well as 𝛼-SMA staining of liver cells, the
same as in theCCl
4
model. In the TAAmodel, administration
of kaerophyllin from Bupleurum scorzonerifolium reversed
histopathological changes and further reduced the levels of
proinflammatory cytokines TNF-𝛼, IL-1𝛽, and MCP-1 [34].
It is worth mentioning that Fuzheng Huayu formula, a
traditional Chinese medicine that showed antifibrotic effects
in clinical practice, also demonstrated significant in vivo
4 Evidence-Based Complementary and Alternative Medicine
Ta
bl
e
1:
A
ni
m
al
m
od
el
so
fN
A
FL
D
an
d
N
A
SH
us
ed
to
in
ve
st
ig
at
et
he
eff
ec
to
fh
er
ba
lm
ed
ic
in
es
.
M
od
el
(in
gr
ed
ie
nt
s)
D
ur
at
io
n
H
er
ba
lm
ed
ic
in
e
Pa
th
ol
og
ic
al
an
d
bi
oc
he
m
ic
al
ch
an
ge
s;
m
ec
ha
ni
sm
si
nv
ol
ve
d
Re
fe
re
nc
e
D
iet
in
du
ce
d
m
od
els
(h
ig
h
ca
lo
rie
s/f
at
sd
iet
)
10
%
la
rd
oi
la
nd
2%
ch
ol
es
te
ro
l
4w
k
Si
Ju
n
Zi
Ta
ng
(S
JZ
),
Li
zh
on
g
Ta
ng
(L
Z)
,L
in
gg
ui
Zh
ug
an
Ta
ng
(L
G
ZG
),
an
d
Sh
en
Zh
uo
Ta
ng
(S
Z)
Re
du
ce
d
ep
id
id
ym
al
fa
ti
nd
ex
an
d
he
pa
tic
fa
ts
in
fil
tr
at
io
n;
re
du
ce
d
tr
ig
ly
ce
rid
es
an
d
A
LT
le
ve
ls.
[8
4]
M
et
hi
on
in
ea
nd
ch
ol
in
eb
ita
rt
ra
te
ta
bl
et
s
4w
k
A
lk
al
oi
ds
of
Ru
bu
sa
lce
ifo
liu
s
Re
du
ce
d
he
pa
tic
lo
bu
le,
se
ru
m
A
LT
,A
ST
,T
N
F𝛼
,a
nd
IL
-6
;h
ep
at
ic
SO
D
an
d
M
D
A
.
[1
6]
25
%
la
rd
,2
%
ch
ol
es
te
ro
l0
.5
%
so
di
um
ch
ol
at
e,
an
d
25
%
Tw
ee
n-
80
56
d
Sc
hi
sa
nd
ra
ch
in
en
sis
Ba
ill
Re
du
ce
d
SO
D
,s
er
um
TC
,a
nd
LD
LC
an
d
in
cr
ea
se
d
he
pa
tic
M
D
A
.
[8
5]
12
%
la
rd
oi
l,
2%
ch
ol
es
te
ro
l,
0.
2%
pr
op
yl
th
io
ur
ac
il,
an
d
0.
5%
bi
le
sa
lt
6w
k
Sa
pi
nd
us
m
uk
or
os
si
G
ae
rt
n.
In
cr
ea
se
d
fa
td
ep
os
iti
on
,f
at
-s
to
rin
g
ce
lls
pr
ol
ife
ra
tio
n,
co
lla
ge
n
ac
cu
m
ul
at
io
n,
m
ac
ro
ve
sic
ul
ar
ste
at
os
is,
ba
llo
on
in
g
de
ge
ne
ra
tio
n,
an
d
cy
to
pl
as
m
ic
va
cu
ol
at
io
n
(m
od
el
gr
ou
p)
.R
ed
uc
ed
liv
er
ce
ll
vo
lu
m
e,
he
pa
tic
lo
bu
le
s,
an
d
fa
td
ro
pl
et
s(
tre
at
m
en
tg
ro
up
).
Re
du
ce
d
TC
,T
G
,L
D
L-
C,
A
LT
,
an
d
A
ST
;i
nc
re
as
ed
A
PN
le
ve
li
n
tre
at
m
en
tg
ro
up
.
[8
6]
10
%
la
rd
,2
%
ch
ol
es
te
ro
l,
0.
2%
bi
le
sa
lts
,1
5%
su
cr
os
e,
8%
ba
ki
ng
so
yb
ea
n
po
w
de
r
7w
k
TZ
Q
fo
rm
ul
a(
re
d
pe
on
y
ro
ot
,
m
ul
be
rr
y
le
af
,l
ot
us
le
af
,d
an
sh
en
ro
ot
,a
nd
ha
w
th
or
n
le
af
)
In
cr
ea
se
d
he
pa
tic
ste
at
os
is,
ne
cr
os
is,
an
d
in
fla
m
m
at
or
y
ce
ll
in
fil
tr
at
io
n
(m
od
el
gr
ou
p)
.R
ed
uc
ed
TC
,T
G
,L
D
L-
C,
H
D
L-
C,
an
d
TC
-H
D
L/
H
D
L
in
tre
at
m
en
tg
ro
up
.
[8
7]
88
%
no
rm
al
ch
ow
pl
us
10
%
la
rd
pl
us
2%
ch
ol
es
te
ro
l
4w
k
+
4w
k
tre
at
m
en
t
Jia
ng
Zh
iG
ra
nu
le
Im
pr
ov
ed
he
pa
tic
ste
at
os
is,
re
du
ce
d
A
LT
an
d
A
ST
,a
nd
im
pr
ov
ed
fre
ef
at
ty
ac
id
an
d
tr
ia
cy
lg
ly
ce
ro
ll
ev
els
.R
ed
uc
ed
LX
R
al
ph
aa
nd
SR
EB
P-
1c
.
[8
8]
M
CD
di
et
8w
k
Fu
zh
en
g
H
ua
yu
re
ci
pe
M
od
el
gr
ou
p
sh
ow
ed
di
so
rie
nt
ed
lo
bu
le,
m
ac
ro
ste
at
os
is,
he
pa
to
cy
te
ne
cr
os
is,
an
d
in
fla
m
m
at
or
y
in
fil
tr
at
io
n.
Tr
ea
tm
en
tg
ro
up
re
du
ce
d
A
LT
,
A
ST
an
d
P4
50
2E
1,
TN
F𝛼
,a
nd
IL
-6
.I
nc
re
as
ed
H
O
-1
.I
nh
ib
ite
d
al
ph
a-
SM
A
,
TG
F-
𝛽
1,
an
d
C
ol
Ia
nd
C
ol
II
I.
[1
7]
H
ig
h
fa
td
ie
t∗
8w
k
Pi
ng
-ta
ng
re
ci
pe
Su
pp
re
ss
ed
vi
sc
er
al
fa
ta
cc
um
ul
at
io
n,
en
ha
nc
ed
gl
uc
os
em
et
ab
ol
ism
,a
nd
am
el
io
ra
te
d
he
pa
tic
ste
at
os
is.
U
pr
eg
ul
at
ed
PG
C-
1a
lp
ha
,P
PA
R
al
ph
a,
an
d
ga
m
m
aa
nd
re
du
ce
d
SR
EB
P-
1c
,F
A
S,
an
d
FA
BP
;a
ct
iv
at
ed
A
M
PK
an
d
ac
et
yl
C
oA
ca
rb
ox
yl
as
ep
ho
sp
ho
ry
la
tio
n.
[2
5]
H
ig
h
fa
ta
nd
hi
gh
fr
uc
to
se
di
et
∗
9w
k
Pu
er
ar
ia
er
ad
ix
,L
yc
iu
m
ba
rb
ar
um
,C
ra
ta
eg
us
pi
nn
at
ifi
da
,
an
d
Po
ly
go
na
ti
rh
iz
om
a
Re
du
ce
d
fa
st
in
g
bl
oo
d
gl
uc
os
ea
nd
im
pr
ov
ed
in
su
lin
re
sis
ta
nc
e.
[8
9]
10
%
la
rd
,1
.5
%
ch
ol
es
te
ro
l,
0.
2%
so
di
um
de
ox
yc
ho
lat
e,
5%
su
ga
r,
0.
05
%
pr
ot
hi
op
yr
im
id
in
e
10
w
k
(5
w
k
tre
at
m
en
t)
Yi
qi
hu
ox
ue
de
co
ct
io
n
an
d
so
lu
tio
ns
of
he
rb
s
H
ep
at
ic
fa
td
ep
os
it,
m
ac
ro
ve
sic
ul
ar
ste
at
os
is,
ba
llo
on
in
g
de
ge
ne
ra
tio
n,
an
d
cy
to
pl
as
m
ic
va
cu
ol
at
io
n
(m
od
el
gr
ou
p)
;r
ed
uc
ed
lip
id
de
ge
ne
ra
tio
n,
fa
t
dr
op
let
sa
nd
sm
al
le
rl
iv
er
ce
lls
,a
nd
de
lin
ea
te
d
he
pa
tic
lo
bu
le
s(
tre
at
m
en
t
gr
ou
p)
.
[9
0]
9.3
g
A
IN
-9
3M
X,
2.
6g
A
IN
-9
3V
X,
0.
5g
ch
ol
in
eb
ita
rt
ra
te
,1
.1
g
D
L-
m
et
hi
on
in
e,
57
.5
g
la
ct
al
bu
m
in
hy
dr
ol
ys
at
e,
117
.5
g
de
xt
ro
se
,3
6.
6m
L
fis
h
oi
l,
an
d
4.
5g
su
sp
en
di
ng
ag
en
tK
12
w
k
Ly
ciu
m
ba
rb
ar
um
po
ly
sa
cc
ha
rid
es
Re
du
ce
d
lip
id
dr
op
le
ta
cc
um
ul
at
io
n,
in
fla
m
m
at
or
y
ce
lls
in
fil
tr
at
io
n,
an
d
he
pa
to
cy
te
ne
cr
os
is
as
ob
se
rv
ed
in
m
od
el
gr
ou
p.
Re
du
ce
d
ph
os
ph
or
yl
at
io
n
of
TG
F-
𝛽
1a
nd
𝛼
-S
M
A
.D
ec
re
as
ed
SR
EB
P-
1c
an
d
PP
A
R𝛾
2,
bu
tr
ed
uc
ed
AT
G
L
an
d
ad
ip
on
ec
tin
;r
es
to
re
d
an
tio
xi
da
nt
en
zy
m
es
;r
ed
uc
ed
N
F-
𝜅
B,
p-
p3
8
M
A
PK
,a
nd
en
ha
nc
ed
au
to
ph
ag
y.
[1
5]
H
ig
h
fa
td
ie
t∗
12
w
k
Ch
in
es
em
ed
ic
in
er
ec
ip
es
Tr
ea
tm
en
tg
ro
up
bl
oc
ke
d
fa
tty
de
ge
ne
ra
tio
n.
D
ec
re
as
ed
ex
pr
es
sio
ns
of
JN
K
an
d
p-
JN
K.
[9
1]
Evidence-Based Complementary and Alternative Medicine 5
Ta
bl
e
1:
C
on
tin
ue
d.
M
od
el
(in
gr
ed
ie
nt
s)
D
ur
at
io
n
H
er
ba
lm
ed
ic
in
e
Pa
th
ol
og
ic
al
an
d
bi
oc
he
m
ic
al
ch
an
ge
s;
m
ec
ha
ni
sm
si
nv
ol
ve
d
Re
fe
re
nc
e
5.
3k
ca
l/g
(fa
t5
9%
,p
ro
te
in
16
%
,a
nd
ca
rb
oh
yd
ra
te
24
%
)
15
w
k
Yi
n-
Ch
en
-H
ao
-T
an
g
Re
du
ce
d
he
pa
to
cy
te
fo
am
in
g
an
d
ba
llo
on
in
g.
Re
du
ce
d
TN
F-
𝛼
an
d
M
CP
-1
.
Pr
om
ot
ed
se
ne
sc
en
ce
m
ar
ke
rp
ro
te
in
-3
0
m
et
ab
ol
ism
.R
es
to
re
d
ox
id
at
iv
e
str
es
sm
ar
ke
rs
.
[9
2]
45
kc
al
%
fa
t,
20
kc
al
%
pr
ot
ei
n,
an
d
35
kc
al
%
ca
rb
oh
yd
ra
te
16
w
k
G
ar
ci
ni
ac
am
bo
gi
as
up
pl
em
en
t
In
cr
ea
se
d
co
lla
ge
n
de
po
sit
io
n
in
tre
at
m
en
tg
ro
up
.R
ed
uc
ed
ob
es
ity
,b
ut
in
du
ce
d
he
pa
tic
fib
ro
sis
(in
fla
m
m
at
io
n
TN
F-
𝛼
an
d
M
CP
-1
an
d
ox
id
at
iv
e
st
re
ss
SO
D
,G
SH
-P
x,
an
d
TB
A
RS
in
cr
ea
se
d)
.
[9
3]
A
xu
ng
ia
po
rc
i1
0%
,c
ho
le
ste
ro
l1
.5
%
,
an
d
bi
le
sa
lt
0.
5%
16
w
k
Ch
ai
hu
-S
hu
ga
n-
Sa
n
an
d
Sh
en
-li
ng
-b
ai
-z
hu
-S
an
M
od
el
gr
ou
p
sh
ow
ed
m
ic
ro
ve
sic
ul
ar
an
d
m
ac
ro
ve
sic
ul
ar
ste
at
os
is,
lo
bu
la
r,
an
d
po
rt
al
in
fla
m
m
at
io
n
an
d
he
pa
to
cy
te
ba
llo
on
in
g
w
hi
le
tre
at
m
en
tg
ro
up
im
pr
ov
ed
th
em
.D
ec
re
as
ed
TN
F-
al
ph
aa
nd
IL
-6
in
se
ru
m
,i
nh
ib
ite
d
TL
R4
,
an
d
ac
tiv
at
io
n
of
p3
8
M
A
PK
.
[9
4]
H
ig
h
fa
td
ie
t∗
16
w
k
So
ot
hi
ng
liv
er
an
d
in
vi
go
ra
tin
g
sp
le
en
re
ci
pe
s
Re
du
ce
d
TC
,L
D
L-
C,
TC
,a
nd
TG
in
tre
at
m
en
tg
ro
up
.R
ed
uc
ed
TL
R4
ex
pr
es
sio
n.
[9
5]
21
.9
kJ
/g
,6
0%
fa
t,
20
%
pr
ot
ei
n,
an
d
20
%
ca
rb
oh
yd
ra
te
20
w
k
Tr
ox
er
ut
in
D
ec
re
as
ed
ep
id
id
ym
al
ad
ip
os
et
iss
ue
m
as
s,
lip
id
ac
cu
m
ul
at
io
n,
an
d
lip
id
le
ve
ls
in
tre
at
m
en
tg
ro
up
.S
up
pr
es
se
d
N
A
D
(+
)d
ep
le
tio
n,
in
cr
ea
se
d
N
A
M
PT
,a
nd
de
cr
ea
se
d
PA
RP
1.
In
cr
ea
se
d
Si
rT
1a
nd
A
M
PK
an
d
in
hi
bi
te
d
m
TO
RC
1a
nd
Lp
in
1𝛽
/𝛼
.
[9
6]
60
%
of
kc
al
as
fa
tw
ith
an
en
er
gy
de
ns
ity
of
5.
24
kc
al
/g
24
w
k
Cr
ud
ee
xt
ra
ct
of
Ly
ciu
m
ba
rb
ar
um
po
ly
sa
cc
ha
rid
e
Lo
w
er
ed
TC
,L
D
L,
TG
,a
nd
D
AG
le
ve
ls.
In
du
ce
d
ph
os
ph
or
yl
at
io
n
of
A
M
PK
,r
ed
uc
ed
nu
cle
ar
ex
pr
es
sio
n
of
SR
EB
P-
1c
,a
nd
in
cr
ea
se
d
U
CP
1a
nd
PG
C-
1a
lp
ha
in
ad
ip
os
et
iss
ue
.
[6
2]
60
%
kc
al
fro
m
la
rd
/s
oy
be
an
9.8
:1
4m
o
+
40
d
tre
at
m
en
t
Rh
ei
n
St
ea
to
tic
an
d
en
la
rg
ed
he
pa
to
cy
te
s(
m
od
el
gr
ou
p)
;r
ed
uc
ed
lip
id
ac
cu
m
ul
at
io
n
(tr
ea
tm
en
tg
ro
up
).
Re
du
ce
d
A
LT
,T
C,
LD
L,
an
d
TG
le
ve
li
n
tre
at
m
en
tg
ro
up
an
d
im
pr
ov
ed
in
su
lin
re
sis
ta
nt
.S
up
pr
es
se
d
SR
EB
P-
1c
an
d
LX
R;
in
hi
bi
te
d
T-
BE
T,
an
d
en
ha
nc
ed
G
AT
A-
3
an
d
pS
TA
T3
.
[14
]
15
%
fa
t,
15
%
su
cr
os
e,
an
d
2%
ch
ol
es
te
ro
l
12
w
k
Sa
lv
ia
-N
elu
m
bi
ni
sn
at
ur
al
is
Re
du
ce
d
m
ac
ro
ve
sic
ul
ar
ste
at
os
is,
TG
,L
D
L-
C,
an
d
FF
A
le
ve
ls.
In
cr
ea
se
d
IR
S
an
d
A
kt
ph
os
ph
or
yl
at
io
n
an
d
de
cr
ea
se
d
SO
CS
3.
[9
7]
H
ig
h
fa
td
ie
t∗
∗
Ci
gu
Xi
ao
zh
ip
ill
s
M
od
el
gr
ou
p
sh
ow
ed
ad
ip
os
ed
eg
en
er
at
io
n
an
d
in
fla
m
m
at
or
y
ce
ll
in
fil
tr
at
io
n.
Tr
ea
tm
en
tg
ro
up
re
du
ce
d
TG
,T
C,
A
LT
,A
ST
,a
nd
M
D
A
le
ve
l
w
hi
le
in
cr
ea
se
d
SO
D
an
d
G
PX
.R
ed
uc
ed
TN
F𝛼
.
[9
8]
M
od
els
de
ve
lo
pe
d
by
co
m
bi
ne
d
in
su
lts
Ap
oE
(−
/−
)+
hi
gh
ch
ol
es
te
ro
ld
ie
t∗
4w
k
H
ua
ng
lia
n
Jie
du
de
co
ct
io
n
A
m
eli
or
at
ed
pa
th
ol
og
ic
al
ch
an
ge
si
n
fa
tty
liv
er
.A
ss
oc
ia
te
d
w
ith
in
cr
ea
se
of
M
2
m
ac
ro
ph
ag
es
po
pu
la
tio
ns
.
[2
0]
M
CD
di
et
in
db
/d
b
m
ic
e
4w
k
Sh
o-
sa
ik
o-
to
(T
J-
9)
,i
nc
hi
n-
ko
-to
(T
J-
13
5)
,j
uz
en
-ta
ih
o-
to
(T
J-
48
),
an
d
ke
ish
i-b
uk
ur
yo
-g
an
(T
J-
25
)
TJ
-9
an
d
TJ
-4
8
re
du
ce
d
A
LT
.N
ec
ro
in
fla
m
m
at
io
n,
he
pa
tic
lo
bu
le
s,
ste
at
os
is,
an
d
ba
llo
on
in
g
de
ge
ne
ra
tio
n.
Re
du
ce
d
TG
F-
𝛽
1,
in
cr
ea
se
d
TN
F𝛼
,
IL
-6
,a
nd
PP
A
R-
ga
m
m
a,
an
d
re
du
ce
d
M
D
A
.
[2
1]
H
ig
h
fa
td
ie
t∗
+
str
ep
to
zo
to
ci
n
i.p
.
4w
k
po
m
eg
ra
na
te
flo
w
er
s
po
ly
ph
en
ol
s
Re
du
ce
d
fa
td
ro
ps
,n
on
-H
D
L-
C,
an
d
tr
an
sa
m
in
as
e.
A
nt
io
xi
da
nt
ab
ili
ty
en
ha
nc
ed
an
d
PO
N
1i
nc
re
as
ed
in
liv
er
.
[19
]
H
ig
h
fa
td
ie
t(
10
%
la
rd
an
d
2%
ch
ol
es
te
ro
l)
+
CC
l 4
8w
k
D
an
gy
ao
(S
we
rt
ia
ps
eu
do
ch
in
en
sis
H
ar
a)
an
d
Sh
ui
fe
iji
(S
ily
bu
m
m
ar
ia
nu
m
G
ae
rt
n.
)
A
m
el
io
ra
te
d
he
pa
to
ste
at
os
is
lo
bu
le
sb
al
lo
on
in
g
de
ge
ne
ra
tio
n
an
d
in
fla
m
m
at
or
y
in
fil
tr
at
io
n
as
ob
se
rv
ed
in
m
od
el
gr
ou
p.
Re
du
ce
d
A
LT
,A
ST
,
TA
G
,a
nd
M
D
A
.I
nc
re
as
ed
U
CP
2.
[1
8]
H
ig
h
fa
td
ie
t(
88
%
no
rm
al
ch
ow
+
10
%
la
rd
+
2%
ch
ol
es
te
ro
l)
+
CC
l 4
8w
k
D
an
gf
ei
Li
ga
nn
in
g
ca
ps
ul
es
Im
pr
ov
ed
ste
at
os
is,
he
pa
to
cy
te
ba
llo
on
in
g,
an
d
in
fla
m
m
at
or
y
in
fil
tr
at
io
n
as
ob
se
rv
ed
in
m
od
el
gr
ou
p.
Im
pr
ov
ed
M
D
A
an
d
A
LT
.
[9
9]
6 Evidence-Based Complementary and Alternative Medicine
Ta
bl
e
1:
C
on
tin
ue
d.
M
od
el
(in
gr
ed
ie
nt
s)
D
ur
at
io
n
H
er
ba
lm
ed
ic
in
e
Pa
th
ol
og
ic
al
an
d
bi
oc
he
m
ic
al
ch
an
ge
s;
m
ec
ha
ni
sm
si
nv
ol
ve
d
Re
fe
re
nc
e
10
%
la
rd
+
2%
ch
ol
es
te
ro
l+
CC
l 4
8w
k
So
ot
hi
ng
liv
er
an
d
in
vi
go
ra
tin
g
sp
le
en
re
ci
pe
s
Re
du
ce
d
SR
EB
P-
1a
nd
SC
D
-1
.
[1
00
]
H
ig
h
ch
ol
es
te
ro
l∗
di
et
in
KK
-A
y
m
ic
e
10
w
k
C
or
os
ol
ic
ac
id
Re
du
ce
d
bl
oo
d
ch
ol
es
te
ro
la
nd
liv
er
ch
ol
es
te
ro
lc
on
te
nt
.I
nh
ib
ite
d
ac
tiv
ity
of
ch
ol
es
te
ro
la
cy
ltr
an
sfe
ra
se
.
[1
01
]
H
ig
h
fa
td
ie
t(
64
0k
ca
l/1
00
g)
+
go
ld
-th
io
gl
uc
os
e
12
w
k
Bo
fu
tsu
sh
os
an
Bl
oc
ke
d
he
pa
tic
ste
at
os
is,
in
fla
m
m
at
io
n,
he
pa
to
cy
te
ba
llo
on
in
g,
an
d
M
al
lo
ry
-D
en
k
bo
di
es
.R
ed
uc
ed
A
LT
,A
ST
,a
nd
TG
le
ve
ls.
In
du
ce
d
ad
ip
on
ec
tin
an
d
its
re
ce
pt
or
s,
in
cr
ea
se
d
PP
A
R-
𝛼
an
d
PP
A
R-
𝛾
,a
nd
de
cr
ea
se
d
SR
EB
P-
1c
;r
ed
uc
ed
IR
by
ph
os
ph
or
yl
at
ed
A
kt
.
[2
4]
H
F
di
et
(19
.6
%
ca
rb
oh
yd
ra
te
s,
18
.2
%
pr
ot
ei
ns
,a
nd
62
.2
%
lip
id
s;
to
ta
le
ne
rg
y,
50
6k
ca
l/1
00
)a
nd
30
%
su
cr
os
ei
n
dr
in
ks
12
w
k
G
os
ha
jin
ki
ga
n
Re
du
ce
d
A
ST
.I
nc
re
as
ed
bo
dy
an
d
ad
ip
os
et
iss
ue
w
ei
gh
ta
nd
re
du
ce
d
ele
va
te
d
liv
er
w
ei
gh
t.
[1
02
]
∗
C
on
te
nt
no
ts
pe
ci
fie
d
in
th
ep
ap
er
.
Evidence-Based Complementary and Alternative Medicine 7
effect in DEN and CCl
4
models [35–38]. Currently, the
Fuzheng Huayu formula is in a phase IV multicenter clinical
trial for HBV induced liver cirrhosis [39]. In DMN-induced
mice, administration of Fuzheng Huayu formula reduced
inflammatory cell infiltration and collagen accumulation and
lowered 𝛼-SMA expression. The antifibrotic effect of the
extract is believed to downregulate TGF-𝛽1 and p-Smad2/3 in
injured tissue [35] as well as attenuating apoptosis via TNF𝛼
blockade [36]. Our research group has extensively studied
the Coptidis rhizoma aqueous extract (CRAE), a traditional
Chinese medicine used in clinical practice for liver disease.
Simultaneous administration of CRAE and CCl
4
for 8 weeks
alleviated the formation of fibrous septa, pseudo lobes, and
collagen deposition. The effect is comparable to that of bear
bile, a medicine traditionally used for liver disease, which
is also effective in CCl
4
induced, cholestatic, and alcohol
fed murine models [40]. The protective effect of Coptidis
rhizoma extracts may be secondary to ameliorating oxidative
stress and decreasing apoptosis [41]. Proposed mechanisms
of action of herbal medicines in liver fibrosis/cirrhosis and
the models used to test them are summarized in Table 2.
Liver fibrogenesis results from excessive deposition of
extracellular matrix and is part of a wound healing pro-
cess triggered by activation of hepatic stellate cells. The
process is accompanied by cell necrosis, apoptosis, and
inflammation [27]. TGF-𝛽1 plays an important role in liver
injury, by regulating the inflammation process, hepatocyte
apoptosis, and the transformation of hepatic stellate cells to
myofibroblasts. Transformed myofibroblasts secrete matrix
metalloproteinases (MMPs) that degrade the extracellular
matrix of normal cells and further promote deposition of
fibrillar collagens [26].Due to the large number ofmyofibrob-
lasts and collagen deposited in fibrotic regions, the hepatic
expressions of 𝛼-SMA and type I/II collagen also increase
significantly. Therefore, these biochemical markers as well as
the inflammatory factors MCP-1 and TNF𝛼 frequently used
to evaluate the effect of herbalmedicines in experimental liver
fibrosis models.
Cholestatic models where bile efflux is impeded through
induction of obstructive bile duct injury are also frequently
used to study the effect of herbalmedicines on biliary fibrosis.
After surgical bile duct ligation, animals develop periportal
hepatocyte necrosis, liver failure, and fibrosis within one
week. Inflammatory cell infiltration, hepatocyte apoptosis,
and collagen deposition are observed in 4 weeks after bile
duct ligation. This murine surgical model is often used
because it is fast and reproducible, even though it can result
in high mortality within a few weeks, an outcome that does
notmirror the slowprogression of the disease in humans [29].
In animals, undergoing bile duct ligation with administration
of huangqi extract restored expression of TGF-𝛽1, 𝛼-SMA,
albumin, and CK7 markers [42]. Proposed mechanisms for
the actions of herbal medicines on biliary fibrosis andmodels
used to study the effects are summarized in Table 3.
4. Animal Models for HCC
Exposure to a variety of agents can lead tomalignant transfor-
mation of hepatocytes, a multistep process characterized by
recurrent genetic modifications. HCC is the most common
type of primary hepatic cancer. Its development is related to
several risk factors such asHBVandHCV infection, alcoholic
liver disease, and NAFLD as well as exposure to environmen-
tal toxins such as aflatoxins and diethyl nitrosamine [43].The
most effective treatment for HCC is surgical removal of the
affected liver tissue followed by liver transplantation. Because
HCC is most commonly diagnosed in late stages where
extrahepatic metastasis is often present, early therapeutic
interventions have not been explored at length.
Not surprisingly, some of these disease-causing agents
mentioned above have been used to establish animal models
for HCC. There are HBV/HCV transgenic mice models as
well as models in which genetic alterations are induced
through either knocking out of tumour suppressor genes
or overexpressing c-myc or TGF-𝛼 protooncogenes. These
models retain some features of the multistep processes of
HCC development in humans and are frequently used to
delineate the role of specific genes in hepatocarcinogenesis as
well as studying the outcome of host-tumour interactions on
disease progression [44]. Choedon et al. [45] used aHBx15-c-
mycmousemodel forHCC, inwhich a truncatedHBx allele is
overexpressed together with c-myc, to show thatThapring, a
traditional Tibetan medicine, restores liver function after 10
months of treatment with concomitant reduction in serum
of SOD and VEGF levels. The significant antitumour effect
of Thapring is presumably linked to increased expression of
p21Waf1 and the apoptosis [45].
Xenograft models in which tumour cell suspensions are
implanted subcutaneously in mice have been extensively
used to monitor tumour growth and effectiveness of new
therapies. This is often the first-line model for anticancer
agent screening in vivo. Recent study by the National Can-
cer Institute [46] showed up to 45% of anticancer agents
confirmed to be clinically effective demonstrated cytotoxic
effects in xenograft models of HCC. The H22 xenograft
model that is established through injection with H22 cell
lines is particularly attractive among other models, due to
the relatively short induction time to develop solid tumours
(approximately 2 weeks). Both subcutaneous and intraperi-
toneal injections can induce solid tumour formation [47]
although the details for this cell line are not well described
in the literature. Administration of Eupolyphaga sinensis
inhibited H22 tumour growth by promoting secretion of
TNF-𝛼 and IFN-𝛾 as well as inducing apoptosis via increased
Bax/Bcl-2 ratio and caspase-3 production [48]. Furthermore,
coadministration of chemotherapeutic agents together with
herbal medicines significantly increased the cytotoxic effects.
Cao and colleagues [49] showed that coadministration of
Fuzheng-Yiliu granules with low dose 5-fluorouracil potenti-
ated antitumour activity and restored white blood cell count.
Similarly, combination treatment ofChaiqiyigan granulawith
taxol had a stronger antitumour effect than that of taxol alone
[50]. Using xenograftmodels, our research group has shown a
potent antitumour effect ofCoptidis rhizoma aqueous extract.
The effect was associated with decreased levels of markers for
cell proliferation and vessel density such as Ki67 and CD31
[51, 52].
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Table 3: Animal models of biliary fibrosis used to investigate the effect of herbal medicines.
Model Experimentdurations Herbal medicine Pathological and biochemical changes; mechanism involved
Reference
Bile duct
ligation
3 days
Aqueous extract from
the root of Platycodon
grandiflorum
Blocked ALT and AST. Restored antioxidant enzymes. High dose
showed lesser hepatocyte necrosis and inflammatory cell
infiltration.
[144]
2 weeks Yang-Gan-wan Reduced 𝛼1 (I) procollagen and 𝛼-SMA. [145]
2 weeks Artemisia capillaris Reduced cholestatic markers and Hyp. Blocked liver injury andcollagen deposition. Reduced 𝛼-SMA, PDGF, and TGF-𝛽.
[146]
28 days Green tea polyphenol
Reduced portosystemic shunting, fibrosis, intrahepatic
angiogenesis, and mesenteric window vascular density. Decreased
HIF-1𝛼, VEGF, and phospho-Akt.
[147]
4 weeks Huangqi decoction Reduced fibrosis degree. Increased Hyp content, CK7, and 𝛼-SMA. [148]
4 weeks Huangqi decoction Blocked collagen deposition. Reduced ALT, Tbil, and Hyp.Inhibited TGF-𝛽1, its receptors, SMAD3, and pERK1/2.
[42]
7 weeks Inchinko-to Decreased ALT and AST. Reduced TGF-𝛽1 and 𝛼-SMA. [149]
Orthotopic models in which tumour cells are implanted
directly into the organ of interest are considered more
clinically relevant and better predictive models for drug
efficacy because the emerging liver tumours better reflect
the niche microenvironment. Although this model is more
technically demanding, it recapitulates key events of the
human disease, such as displacement of the normal cell
population by tumour formation as well as the production
of circulating metastatic tumour cells. Wang and colleagues
[53] implantedHepG2 cells expressing red fluorescent protein
into mouse livers and monitored tumour growth and metas-
tasis by fluorescence imaging. Metastatic spread to pancreas
and mediastinal lymph nodes was observed after 25 days
of post-HepG2 implantation. Early treatment with Celastrus
orbiculatus effectively blocked tumour growth. Similar to
observations made in humans regarding the administration
of chemotherapeutics in later stages of liver disease, the effect
of Celastrus orbiculatus became less significant when the
treatment was started after the tumours formed. In a pre-
vious study, we also implanted luciferase-tagged MHCC97L
tumours into BalB/c nude mice in order to observe the effect
of berberine, the major ingredient of Coptidis rhizome. The
treatment effectively suppressed tumour growth and lung
metastasis [54]. Some of the antitumour mechanisms of
herbal medicines in liver cancer and the models used are
summarized in Table 4.
5. Animal Models for Acute Liver Injury
There is a growing number of studies describing the effect
of herbal medicines in acute liver failure. Acute liver failure
is defined as a severe impairment of liver function within
short duration and without a history of preexisting liver
disease. Acute injury leading to liver failure may be less
frequent in the clinic than other forms of liver failure and
yet it is life-threatening [55]. In humans, drug-induced liver
injury (e.g., fromhigh doses of acetaminophen, antibiotics, or
antituberculosis drugs) is the major cause of acute liver fail-
ure. Other leading causes are viral infections and accidental
toxicity such as excessive alcohol consumption or mushroom
poisoning as well as those caused by ischemic or metabolic
disorders. Much current herbal medicine research focused
on the hepatoprotective actions of herbal medicines in acute
liver injury models induced by hepatotoxins, chemicals,
or drugs. A list of hepatoprotective herbal medicines and
related animal models is shown in Table 5. Most of these
disease models are of short duration and include studies
of acute biochemical parameters of liver injury such as
liver enzyme levels (i.e., ALT and AST) and inflammatory
markers as well as markers of organ health such as circulating
albumin and total bilirubin. The histological changes for
acute liver injury model are not as significant as the longer-
term model. Yet, it could be identified through the induction
of vacuole formation, infiltration of inflammatory cells, and
hepatocytes necrosis and apoptosis. In many instances, the
toxicity model is established either concurrently or following
the administration of herbal medicines in order to determine
an extract’s hepatoprotective effect. For example, after 15
days of treatment with an aqueous licorice extract, mice
were given an acute oral dose of CCl
4
and sacrificed after
8 hours. Licorice-pretreated mice had significantly lower
circulating liver enzymes and increased antioxidant enzymes
in the liver, such as superoxide dismutase (SOD), catalase
(CAT), glutathione peroxidase (GSH-Px), glutathione reduc-
tase (GR), and glutathione S-transferase (GST), indicating a
hepatotoxic preventive effect from the licorice extract [56]. In
acetaminophen-induced hepatotoxicity, coadministration of
Tournefortia sarmentosa reducedCAT, SOD, andGPx antiox-
idant enzyme levels indicating less liver stress and decreased
levels of inflammatory factors (TNF-𝛼, IL-1𝛽, and IL-6) [57].
Most hepatoprotective herbal medicines reverse liver injury
through attenuation of injury-associated oxidative stress and
inflammation resulting in lower levels of circulating and
total bilirubin. Because at the moment liver transplantation
is the only cure for acute liver failure, there is an urgent
need to further explore the hepatoprotective effect of herbal
medicines.
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6. Discussion
6.1. Mechanisms Associated with Cytoprotective Effects of
Herbal Medicines in Liver Diseases. Oxidative stress is one
of the key drivers of liver disease pathogenesis. Damage by
oxidative stress results when the natural balance between
production and breakdown of reactive oxygen species (ROS)
is disturbed. In NAFLD, beta-oxidation in mitochondria
leads to disturbances in electron transport reactions and
elevates ROS production [58]. ROS has been implicated in
altered hepatocyte ploidy as well as the initiation of genomic
changes that may further promote progression to HCC. In
keeping with the reported deleterious effects of ROS on liver
function, antioxidants contained in herbal remedies were
shown to restore normal hepatocyte ploidy in NAFLD [59].
In the HFD induced NAFLD model, mice fed with excessive
fat showed accelerated mitochondrial and peroxisomal fatty
acids 𝛽-oxidation as well as increased microsomal fatty acid
𝜔-oxidation [60]. Furthermore, ROShas also been implicated
in the CCl
4
model of liver fibrosis. CCl
3
radicals resulting
from administration of CCl
4
interact with oxygen to produce
highly reactive peroxy radicals that promote lipid peroxida-
tion through removing hydrogen groups from unsaturated
fatty acids [61]. One way that herbal medicine contributes to
the amelioration of liver diseases is by improving antioxidant
activity through chemical reduction of malondialdehyde
(MDA) or by boosting glutathione S-transferase (GST) activ-
ity. High concentrations of the antioxidants, terpenes, and
flavonoids in herbal medicines are likely responsible for the
protective effect. In addition, herbal medicines increase the
activity of many liver enzymes involved in ROS scavenging
such as catalase, superoxide dismutase (SOD), and glu-
tathione peroxide (GPx) as well as reducing ROS production
via promoting formation of GSH, the antioxidant. Another
instance of liver protection is associated with upregulation
of UCP, a mitochondrial carrier [18, 62] involved in ROS
metabolism.
Apart from oxidative stress, inflammation is another
principal driver of liver disease. Persistent inflammation can
be triggered through activation of resident macrophages
and infiltration with immune cells from the blood stream
following injury as well as the interaction of immune cells
with surrounding liver tissues [27]. All these will lead
to excessive secretion of proinflammatory cytokines TNF-
𝛼, IL-6, and IL-1𝛽 and further contribute to cell death.
Furthermore, TGF-𝛽 secretion by activated monocytes was
shown to stimulate hepatic stellate cells to increase collagen
production [63]. These observations underscore the impor-
tant role of inflammation-related host-cell interactions in
liver disease. Many herbal medicines possess potent anti-
inflammatory activities that attenuate cytokine or chemokine
production. Although there are few studies reported on how
herbal remedies regulate immune cells or hepatocytes to
attenuate inflammation, several protein targets such as NF-
𝜅B, STAT3, and AMPK have been suggested. By inhibiting
these pathways, some herbal remedies effectively protect the
liver against inflammation-induced damage.
6.2. In Vitro Models for Liver Diseases. To date, herbal
medicine research in liver diseases, particularly NAFLD/
NASH and fibrosis, rarely employed in vitro cell models
because of their limitation in mimicking clinical pathogen-
esis. Although immortalized cell lines and primary cultures
have been used for herbal medicine studies, interactions
between different cell types and the influence of extracellular
matrix as well as other aspects in the niche microenviron-
ment, which are significant disease-contributing factors in
humans, cannot be replicated in cell culture models. Using
nonalcoholic fatty liver disease as an example, interactions
between adipocytes and hepatocytes regulate secretion of free
fatty acids that further promotes the transition of hepatocytes
and surrounding nonparenchymal cells towards the disease
state. Thus, many factors need to be considered regarding
whether a cellmodel of the liver disease is to produce valuable
translational outcome. Still, due to the simplicity of studying
molecular mechanisms of disease and the ease of obtaining
drug leads, a lot of efforts have been directed at establishing
or optimizing in vitro cell models for high throughput drug
screening. Xu et al. [64] established a TGF-𝛽1 fibrogenesis
two-cell based model that allows efficient quantification of
the effects of antifibrotic drugs on 2D matrix accumulation
and 3D nodule formation. The model has been employed
in kidney fibroblasts for the screening of Chinese medicine
compounds and herb extracts for inflammation independent
antifibrotic activity [65]. Another model established by Chen
et al. [66] is the “scar-in-a-jar” model that improves current
fibroplasiamodels by incorporating in situ optical bioimaging
for cell and collagen quantitation. Yet, neither of these two
models has been used at length to screen for antifibrotic
herbal remedies. A substantial leap in our ability to investigate
the use of herbal medicines in liver diseases is expected
to occur following the establishment of new models or
improvement of existing ones.
6.3. Future Perspectives. Due to the limitation of cell models
to provide translatable solutions for clinical applications,
animal models remain important for translating a promising
herbal compound into the clinic. The preferred protocol
is to firstly establish a genetically modified or diet fed
mouse model that exhibits some key aspect of the human
pathogenesis. In humans, liver disease pathogenesis requires
years of genetic evolution and cellular dysfunction in which
processes such as cross talk between parenchymal and non-
parenchymal liver cells aswell as involvement of immune cells
occur. Thus, the effects of herbal medicines on these cellular
processes need to be delineated in order to provide a better
understanding of the processes involved and to facilitate
better translational context for human studies.
Single animal model and short duration studies that aim
to establish the effectiveness of any herbal medicine are
relatively unpersuasive. Typically, such studies use a narrow
spectrumof outcomeswith limitedmeasurement criteria that
may be poorly translatable to human studies. Clearly, even
in complex models, the complete pathogenesis of a specific
liver disease is rarely recapitulated and therefore more than
one animal model is needed to validate the effectiveness of
an herbal remedy. Several herbal medicinesmentioned above
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show a profound reversal of liver diseasemarkers and need to
be studied further. For example, the potent antifibrotic effect
of Yi Guan Jian extract that has been extensively studied in
the CCl
4
model is attributed to the blockade of fibrogenesis
due to bone marrow derived fibrogenic cells in the liver
[67–69]. However, this effect is oxidative stress-dependent
and can only be partially reproduced by administration of
CCl
4
that severely damages the liver and does not reflect
the conditions present in the human disease. Further studies
using different rodent models should be implemented to
eliminate the possibility that the therapeutic effect of this
herbal remedy is due to model-specific bias.
Although preclinical studies have mostly used mouse
models, alternative models based on zebrafish are now
emerging. With a sequenced genome, the zebrafish has
recently emerged as a robust vertebrate model for a variety
of human diseases, including the liver diseases [70, 71].
Zebrafish is amenable to unparalleled ease of embryonic
manipulation and adaptability for high throughput screens.
Furthermore, the physiological similarities between zebrafish
and the humans provide a strong rationale for direct drug
discovery on zebrafish embryos with translational potential
[72, 73]. Zebrafish studies further benefit from a vast array
of newly developed research tools such as genome-wide
ENU mutagenesis, transgenesis, and genome editing/gene
knockout by ZFN, TALENs, and CRISPR. These tools are
readily available to create gene-modified models of liver
diseases that can be applied to large scale screens of herbal
compounds/extract as well as mechanistic studies of disease
progression [74].
Recently, zebrafish has been actively explored as models
forNAFLD and/or steatosis using dietary addition of fructose
[75] or by introducing a slc7a3a mutation to knockout genes
involved in NO-AMPK-PPAR-𝛾 signalling pathway [76].
ENU-mutagenized zebrafish larvae have also been used for
genetic screens aimed at identifying novel genes that con-
tribute to NAFLD/NASH phenotype [77]. Studies towards
the development of zebrafish hepatic fibrosis model showed
that administration of diethylnitrosamine resulted in 80%
of treated zebrafish developing liver fibrosis after 6 weeks
of treatment [78]. In an effort to build spontaneous hepatic
cancer models in zebrafish, either constitutively or by using
chemical inducers of liver-specific promoters, the Gong team
has achieved targeted liver overexpression of a number of
oncogenes such as Kras (V12) and Myc [79–82]. The Stainier
lab has also developed a hepatocyte-specific activated 𝛽-
catenin model in which 78% of transgenic zebrafish devel-
oped hepatocellular carcinoma by 6 months of age [83]. It is
anticipated that these unique genetic zebrafish liver disease
models and others will lead to further mechanistic studies
as well as large-scale screens of herbal medicines in the near
future.
7. Conclusion
Herbal medicines contain a wealth of empirical pharma-
cological outcomes distilled over centuries of practice but
more research efforts should be tried in identifying the active
medicinal ingredients. This rediscovery or modernization of
traditional Chinese medicine holds great promise for new
active compounds with cytoprotective, disease-arresting, and
curative properties. There are still many challenges to estab-
lish relevant animal models for studying the efficacy of the
promising compounds outlined in this review.The process of
animal modelling is crucial to generate valuable translatable
outcomes. Currently, no single model exists that completely
recapitulates the entire pathological progression of NAFLD,
NASH, cirrhosis, HCC, or acute liver injury. Therefore, data
obtained from one model needs to be validated and studied
further in other models. It is anticipated that, by employing
new genome editing technologies such as CRISPR, more
faithful animal models of liver disease will emerge that will
push the current boundaries of herbal medicine research.
While rodentmodels remain paramount for the study of drug
efficacy, mechanism of action, and toxicity, new emerging
zebrafishmodels assisted by a host of recent technologies hold
great promises for high throughput screens of new bioactive
compounds in herbal medicines.
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